Last A$0.0015 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:45 PM 08/11/14 All times are local (Market data is delayed by at least 15 minutes).

tyrian diagnostics ltd (TDX) Snapshot

Open
A$0.0015
Previous Close
A$0.0015
Day High
A$0.0015
Day Low
A$0.0015
52 Week High
01/8/14 - A$0.0030
52 Week Low
08/21/13 - A$0.0010
Market Cap
1.5M
Average Volume 10 Days
500.0K
EPS TTM
A$-0.0001
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TYRIAN DIAGNOSTICS LTD (TDX)

Related News

No related news articles were found.

tyrian diagnostics ltd (TDX) Related Businessweek News

No Related Businessweek News Found

tyrian diagnostics ltd (TDX) Details

Tyrian Diagnostics Limited develops and commercializes diagnosis technologies. It discovers and validates biomarkers for tuberculosis; and develops DiagnostIQ, a proprietary point of care diagnostics platform. The company licenses its core intellectual property assets, including DiagnostIQ device, a small disposable plastic capsule for diagnostic testing; and TB biomarker patents. The company is headquartered in Sydney, Australia.

tyrian diagnostics ltd (TDX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

tyrian diagnostics ltd (TDX) Key Developments

Tyrian Diagnostics Ltd., Annual General Meeting, Oct 30, 2013

Tyrian Diagnostics Ltd., Annual General Meeting, Oct 30, 2013., at 12:00 AUS Eastern Standard Time. Location: Taylor Collison Limited, Level 10. Agenda: To receive and consider the company's Financial Report, the Director's Report and the Independent Auditor's Report in respect of the year ended June 30, 2013; to consider remuneration report; and to elect Mr. Roger Amos as director.

Tyrian Diagnostics Ltd Announces Termination of its Non-Exclusive Licence Agreement with Bayer CropScience AG on September 1, 2014

Tyrian Diagnostics Ltd. announced its non-exclusive licence agreement with Bayer CropScience AG would be terminated on September 1, 2014 in accordance with the terms of the agreement. Under this agreement, which commenced in 2012, Tyrian granted a licence to Bayer to exploit an application on the DiagnostIQ Platform to generate an a-amylase analyte signal from grain samples. To date, no licence fees have been generated from this agreement and the termination will have no impact on the company's forecast cash flow or revenues.

Tyrian Diagnostics Ltd. to Report First Half, 2013 Results on Feb 25, 2013

Tyrian Diagnostics Ltd. announced that they will report first half, 2013 results on Feb 25, 2013

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TDX:AU A$0.00 AUD 0.00

TDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TDX.
View Industry Companies
 

Industry Analysis

TDX

Industry Average

Valuation TDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TYRIAN DIAGNOSTICS LTD, please visit www.tyriandx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.